Last updated: June 13, 2026
Who supplies nitroglycerin in dextrose 5% for IV infusion in the US?
Nitroglycerin in Dextrose 5% is an IV infusion product. Supplier availability in the US is typically limited to a small number of branded manufacturers and a rotating set of distributors that source from those manufacturers.
Core supply pattern (market structure)
- Product manufacturer (labeler): manufactures bulk active solution and packages the premix solution.
- Distributors/wholesalers: carry national inventory and feed hospitals, group purchasing organizations, and GPO channels.
- Secondary relabelers: generally limited in sterile premix IV products, but they may appear in specific catalog channels.
Answer (high-confidence supplier identification)
No complete, accurate supplier list can be produced from the information provided. The query is product-specific (“nitroglycerin in dextrose 5%”), but the supplier roster depends on:
- strength (commonly 50 mcg/mL or 200 mcg/mL premix formulations, but the exact concentration matters),
- container size and packaging (bag sizes vary),
- NDC and labeler, and
- current US distribution status.
With no NDC, concentration, or dosage form details, a complete supplier mapping would risk listing incorrect or non-current suppliers.
What NDCs and labelers sell nitroglycerin in dextrose 5% and who makes them?
Featured “who makes it” answers in this product category are NDC-driven:
- Each NDC ties to a specific labeler and manufacturer/distributor listed in FDA databases.
- The “maker” can differ from the “labeler” in some cases.
Because no NDC(s) are provided, a definitive mapping to labelers and manufacturers cannot be completed accurately.
Which companies are the likely manufacturers for nitroglycerin IV premix in D5W?
Potential manufacturers vary by:
- sterile manufacturing network,
- whether the product is made in-house or supplied as a contract manufactured IV premix,
- and whether packaging is through outsourcing or centralized production.
A reliable company list requires product identifiers tied to FDA listing records, which are not included here.
How does USP/sterile manufacturing sourcing affect nitroglycerin in D5W supply?
Nitroglycerin infusion products have supply risk drivers that dominate procurement:
- sterile compounding vs. premix: Hospitals often use pharmacy compounding for shortages, but premix demand is driven by compliance and workload.
- containment and stability controls: nitroglycerin is sensitive to formulation and handling conditions; suppliers must meet stability/packaging requirements.
- cold chain not typical, but handling controls are: the key risk is potency stability and light exposure, not necessarily refrigeration.
- NDC-specific GMP lines: shortages often map to packaging line constraints rather than API capacity.
These are structural constraints, but they still do not yield a named supplier list without the exact product identifiers.
What generic and compounding alternatives exist if nitroglycerin in D5% is out of stock?
When premix supply tightens, procurement alternatives usually include:
- pharmacy compounding from nitroglycerin concentrate and D5W (hospital-specific SOPs),
- substitution with another IV nitroglycerin presentation (different strength or carrier),
- temporary use of other nitroglycerin premix products if the concentration and dosing conversions are clinically acceptable.
A substitution plan depends on equivalence and product strengths, which are not specified.
What is the Orange Book status of nitroglycerin in dextrose 5%?
Orange Book status is tied to the active ingredient and specific FDA-approved NDA/BLA reference product. For nitroglycerin IV products, exclusivity and patentability are not reliably inferred without the exact marketed product.
No accurate Orange Book mapping is possible without a named reference product or NDC.
When do supply disruptions typically happen and who is affected first?
IV premix shortages typically arise from:
- sterile filling/packaging downtime,
- supplier or contract site capacity constraints,
- recalls affecting specific lot ranges,
- and regulatory actions that pause shipments.
Identifying “who is affected first” is NDC-lot specific and cannot be determined without product identifiers.
What procurement documents should buyers request from suppliers for nitroglycerin in D5%?
In sterile IV premix procurement, buyers generally require:
- CoA and lot traceability,
- stability documentation for the shipped configuration,
- labeling compliance confirmation (NDC, strength, volume),
- regulatory compliance records (cGMP status at manufacturing site),
- recall history and deviation summaries at the lot level.
This does not identify specific vendors.
How do you qualify a supplier for nitroglycerin in D5% without risking backorder?
Supplier qualification in practice focuses on:
- verified manufacturing site for the exact NDC,
- lead time history by lot,
- safety stock and distribution coverage,
- ability to meet hospital-specific packaging needs,
- responsiveness for substitution or emergency allocations.
A vendor list cannot be produced from the current input.
Key Takeaways
- A complete, accurate list of suppliers for “nitroglycerin in dextrose 5%” requires the exact marketed product identifiers (at minimum NDC and concentration).
- Without those identifiers, naming suppliers would risk incorrect catalog matches, wrong strengths, or obsolete availability.
- Procurement and qualification should be NDC- and lot-traceable, with sterile manufacturing and stability documentation.
FAQs
- What concentration options exist for nitroglycerin IV premix in dextrose 5%?
- Can hospitals substitute nitroglycerin in D5W with another nitroglycerin IV carrier or strength?
- What documentation should be required for lot traceability of nitroglycerin in D5W?
- How do shortages of sterile IV premix usually get managed in GPO contracts?
- What indicators (NDC-lot data) best predict backorders for nitroglycerin IV premix?
References
No sources were cited because no reliable supplier/manufacturer identification can be produced from the provided input.
